Figure 4From: Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageAssociation of antitumor activity of lenvatinib with tumor vasculature in 19 human tumor xenograft models. Lenvatinib was administered orally twice daily for 7 days, when tumor volumes reached approximately 100–300 mm3. Each group consisted of 5 mice. (A) Antitumor activity of lenvatinib in 19 human tumor xenograft models. The ΔT/C (%) was presented as a mean. □: The lenvatinib-sensitive group; ■: the lenvatinib-relatively resistant group. The relationship between the antitumor activity and MVD is shown in (B), and that between the antitumor activity and the % of pericyte coverage of vessels is shown in (C). Each symbol (○) indicates the mean of MVD or pericyte coverage in each tumor xenograft model. (D) Vascular score in the lenvatinib-sensitive and –relatively resistant groups. The vascular score was the sum of the MVD and pericyte coverage scores.Back to article page